During the past ten years the reuse of hemodialyzers has been increasing rapidly. Currently, two-thirds of patients are dialyzed with reprocessed dialyzers (1), a situation that has been prompted by both medical and economic reasons (2) . In 1980, the FDA sponsored a report on the risks and hazards associated with hemodialysis devices (3) and the Association for the Advancement of Medical Instrumentation (AAMI) in 1986 recommended procedures for the reprocessing and reuse of hemodialyzers (1) . Yet, theeftects of reprocessing agents, including germicides, on hemodialyzer membranes remain largely unknown, and several biological and physico-chemical issues remain to be resolved.
Background
Of the three known types of dialyzers -coil, parallel plate, and hollow-fiber -the latter are now the most commonly used. Each hollow-fiber dialyzer has over 10,000 fibers with internal diameters of some 200 urn, thus having very high effective membrane surface area. The fibers are made from either cellulosic (natural) or synthetic polymers. In the former category are Cuprophans' (manufactured by the cuprammonium process), cellulose acetate, and Hernophanev (containing tertiary amino groups). The major synthetic polymeric materials include polysulfone, polycarbonate, and polyacrylonitrile-sodium methalyl sulfonate (Hospal® An-69, Hospal Ltd., Basel, Switzerland). Cuprophan't hollow-fiber membranes have inner diameters of 200-215 urn, and outer diameters 260-290 urn (Membrana GmbH, Wuppertal, Federal Republic of Germany). Hollow-fiber membranes can also be prepared by the deacylation of cellulose acetate (pioneered by scientists of the Cordic Dow Corporation) (4), and now marketed by CD Medical, Inc. Depending on the manufacturer, the hollow fibers are embedded in polymers such as polysiloxane, epoxy resin, or polyurethane (5) .
The membrane separation processes involve dialysis, ultrafiltration, and to a lesser degree osmosis (6, 7) . Until a few years ago, new dialyzers were sterilized with ethylene oxide, formaldehyde, other chemicals, and ionizing radiation being used to a lesser extent (8, 9) . Clearly, great care must be taken to ensure the removal of residual sterilizing agents and their degradation products to avoid possible adverse biological consequences (10) (11) (12) .
The germicides or disinfectants used in the re-processing of dialyzers include aqueous formaldehyde, hydrogen solutions, peroxide/peracetic acid mixtures, glutaraldehyde, and chlorine-based chemicals. Various trade names including Renalin® (peroxide/peracetic acid), Sporicidin® (glutaraldehyde), and RenNewD® (CI0 2 ), the latter not on the U.S.A. market at this time.
The blood-contacting as well as the dialysate-contacting surfaces of dialyzers must be subjected to "high-level" disinfectants (Le., 4% aqueous formaldehyde), whereas "low-level" disinfectants (e.g., sodium hypochlorite) may be used for treating the exterior (non-blood contacting and non-dialysate-contacting) of the dialyzers (1). If formaldehyde is used as the "high-level" disinfectant, the maximum level of residual formaldehyde remaining in the dialyzer after rinsing should be no more than 5 ppm (1). It should be noted that the Occupational Safety and Health Administration (OSHA) has reduced the occupational exposure to formaldehyde to below 1.0 ppm (Federal Register, December 4, 1987, 20 CFR Parts 1910 and 1926), but the latest AAMI guidelines on the reuse of hemodiaIyzers (1) is dated 1986. Additionally, the bacterial colony count of water used as a diluent in the preparation of the germicide solution should be less than 200/ml and/or a bacterial lipopolysaccharide concentration of less than 1 ng/ml (1).
Reused hemodia/yzers

Reprocessing and criteria for reuse
The Association for the Advancement of Medical Instrumentation has published a recommended practice on the reprocessing and reuse of hemodialyzers (1) . In accordance with these guidelines, dialyzers in one institution (13) were discarded after reuse if any of the following conditions existed: a) fiber volume of less than 80% of baseline; b) leakage of blood from the dialyzer; c) damage to the external casing; and d) febrile reaction by the patient during dialysis with a reused dialyzer.
It has been recommended that in vitro clearance of small molecules, such as urea or sodium, or a compartment clearance should be used as a criterion for rejecting reused dialyzers as an alternative to ultrafiltration rate (1) . If ultrafiltration rate is used for the determination of membrane resistance as an indirect measure of solute clearance, a ± 10 percent change has been recommended by AAMI as the minimal acceptance criterion (1).
Effects of reuse: first-use syndrome
The use of new hemodialyzers, especially those composed of cellulosic membranes occasionally results in transient leukopenia, manifested by reversible pulmonary vascular leukosequestration (14, 15 ). This appears to be the consequence of the activation of the alternate pathway of the complement system (13, (16) (17) (18) . The activation of the complement system, as indicated by the formation of the anaphylatoxins C3a and C5a, can be induced by the membrane materials. Cellulosic membranes induce complement activation to a far greater extent than synthetic polymers (i.e., polyacrylonitrile, polysulfone) (19, 20) .
It has been shown that formalin-fixed new (unused) hemodialyzers retain their ability to activate complement with formation of the C5a component (13) . On the other hand, because of the generally low residual level of formaldehyde remaining in reused dialyzers (13) , it seems unlikely that this small quantity of fixative may enhance the attachment of various plasma proteins to the membrane surfaces despite suggestion to this effect (13) . It has been claimed (13) that albumin can be eluted from reused hemodialyzers, but further research needs to be done in this area to repli-212 cate this finding. It should be noted that the initial thrombotic events with artificial surfaces have been related, in part, to the adsorption of various plasma proteins from plasma and flowing blood (21) (22) (23) . It is unknown, whether reused and reprocessed dialyzers retain adsorbed plasma proteins on the membrane surfaces, but given the vigorous nature of reprocessing (1) it seems unlikely that such a "passivating" protein coating remains. On the other hand, the C3b antigen remains associated with reused and reprocessed dialyzers (13) . The possible role of a "passivating" protein coating alone is not clear because new (unused) non-cellulosic membranes (Le. polyacrylonitrile) do not elicit leukopenia. Apparently this is so because such synthetic membranes activate the alternate pathway of complement to a much lesser extent than cellulosic membranes (24) . Yet, whatever the mechanism, the use of reprocessed and reused dialyzers has been claimed to reduce the so-called first-use syndrome.
Biologic considerations
During dialysis with reprocessed dialyzers some patients experience febrile reactions. This phenomenon has been used as a criterion to retire reprocessed dialyzers (13) . Hence, there is a need for more specific testing of reprocessed dialyzers prior to their use in patients to avoid such adverse clinical reactions. It is to be noted that the recommended practice suggested by the AAMI (1) for the reuse of hemodialyzers specifies that both the blood and dialysate compartments should be rinsed with cleaning solution until the effluent is.clear and no clots are seen (5). Since the above procedure relies on visual observations rather than on more precise optical and biochemical tests, it is subject to human errors. Similarly, it is possible that germicides may have adverse effects on the biologic residues within the dialyzers (proteineous deposits, complement fragments, etc.) as well as on the dialysis membranes themselves. There is no way of knowing what happens in the above areas during reprocessing as the effluent solution is not subjected to chemical analyses, other than checking the presence or absence of disinfectant/sterilizing products from reused dialyzers.
Another issue concerns the development of amyloidosis, including carpal tunnel syndrome and amyloid arthropathy in patients undergoing long-term hemodialysis (25) (26) (27) (28) . Such amyloidosis has been diagnosed in a wide segment of long-term dialysis patients (29) , with~2-microglobulin identified as a new form of amyloid protein associated with chronic hemodialysis (30) (31) (32) (33) .~2-microglobulin molecules are normally transported through the glomerular membranes and catabolized in the renal tubules (30) . In renal failure there is an increased serum concentration of~2-mic roglobulin and its accumulation could playa role in the genesis of amyloidosis (29) . Some investigations, however, found no correlation between~2-microglob ulin serum levels and clinical or radiological evidence of amyloidosis induced by hemodialysis (31) . Thus, although~2-microglobulin serum levels are elevated, especially so with Cupropharrs membranes, it is by no means clear that using more permeable membranes will prevent the development of amyloidosis (29) (30) (31) (32) (33) (34) . Furthermore, it is not known whether the reuse of diaIyzers plays a role in causing amyloidosis and further studies are needed to clarify this issue.
Physico-chemical considerations
Since hemodialysis membranes are currently made from either cellulosic or synthetic polymers, the repeated use of sterilizing agents and disinfectants is expected to have various physico-chemical effects on the membrane materials, such as altered porosity, degradation, and surface modification. Although a leak test has been recommended to check the effect(s) of disinfectants on reused dialyzers, the eluates might contain degradation products and fragments of the polymeric membranes, in addition to other potentially toxic materials. The latter category includes copper and zinc in Cuprophan'" membranes made by the cuprammonium process (35, 36) although no toxicity has been reported with patients. Residual formaldehyde has been reported to cause burning sensations, neurological and retinal disturbances, hemolysis, and other adverse effects (9, 37) . Residual ethylene oxide and its degradation products may also cause allergic reactions and IgG antibody formation (10, 38) . Similar immune-mediated responses exist when germicides other than ethylene oxide or formaldehyde are used.
It is not currently known what the optimum and maximum number of cycles of reprocessing hemodiaIyzers are. While many dialysis centers average up to seven cycles, others may reprocess dialyzers even 50 or more times. Thus, there is a need to delineate guidelines as to the maximum number of reprocessing cycles based on quantifiable performance parameters. Additionally, the most stringent safeguards must be instituted to insure that a given dialyzer is used in the same patient after reprocessing. This is mandatory especially because of the potential consequences of transmitting HIV virus causing AIDS.
Recommendations
In view of the various uncertainties, especially the intradialytic evolution of serum beta-2-microglobulin (39), validation studies should be conducted in which samples of the effluent after reprocessing of dialyzers have been subjected to biochemical testing of the biological constituent (l.e. residual plasma proteins, complement fragments, formed blood elements). This approach could avoid undesirable clinical effects, such as febrile reactions in some patients undergoing dialysis with reprocessed units.
In addition to leak tests, samples of the effluent after reprocessing of dialyzers should be subjected to various analytical evaluations, for example combined high pressure chromatographic/infrared spectral analyses aimed at detecting potentially toxic degradation product(s) of the dialysis membranes as the result of interaction with sterilants and disinfectants.
Additional tests should include those recommended by AAMI (1), namely to determine fiber bundle volume, solute clearance, absence of residual sterilizing agents and/or disinfectants and germicides, blood leakage, and integrity of the external casing, and standards promulgated by the U.S. Health Care Financing Administration (40) . For the long-term, systematic studies are needed to determine the physico-chemical changes that may occur in dialyzers after reprocessing and reuse, aimed at establishing the optimum and maximum number of reprocessing and reuse cycles for cellulosic and synthetic membrane materials. In addition to destructive tests requiring the 213 disassembly of dialyzers, it may be possible to develop specific non-destructive testing methodologies such as nuclear magnetic resonance imaging and ultrasound imaging of reprocessed dialyzers.
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